Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) has received US Food and Drug Administration (FDA) approval for the company's Abbreviated New Drug Application (ANDA) for Levetiracetam tablets, a biogeneric version of Belgian biopharmaceutical company UCB SA's (Euronext: UCB) Keppra tablets for the treatment of epilepsy.
Taro received FDA approval for four dosages of the tablets: 250 mg, 500 mg, 750 mg, and 1000 mg. According to industry sources, levetiracetam tablets had over $700 million in US sales in 2009.
Taro's share closed at $10.01 on Wall Street yesterday.
Published by Globes [online], Israel business news - www.globes-online.com - on February 2, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments